Aminoglycosides are widely used in cystic fibrosis management. The m.1555A>G mutation predisposes to aminoglycoside ototoxicity. It may cause later onset hearing loss in the absence of aminoglycosides use and gradual hearing loss may be an inevitable consequence of the mutation. Given that aminoglycoside therapy forms the backbone of IV protocols in CF, this article recommends screening for this mutation to allow informed decision-making prior to aminoglycoside administration, to avoid preventable deafness.
Keywords: Aminoglycosides; Cystic fibrosis; Hearing loss; Mitochondrial mutation m.1555A>G..
Crown Copyright © 2016. Published by Elsevier Ltd. All rights reserved.